Literature DB >> 29740872

Prodromal symptoms of multiple sclerosis in primary care.

Giulio Disanto1, Chiara Zecca1, Sharon MacLachlan2, Rosaria Sacco1, Lahiru Handunnetthi3, Ute C Meier4, Alex Simpson2, Laura McDonald5, Andrea Rossi6, Pascal Benkert7, Jens Kuhle8, Sreeram V Ramagopalan5, Claudio Gobbi1.   

Abstract

OBJECTIVE: Early diagnosis and treatment initiation significantly influence long-term disability outcome in multiple sclerosis (MS). We aimed at identifying prodromal symptoms of MS in primary care settings.
METHODS: This was a nested case-control study comparing the occurrence of various symptoms in MS patients versus controls at 0 to 2, 2 to 5, and 5 to 10 years before index date (first MS record). A total of 10,204 incident MS cases were identified within the United Kingdom Clinical Practice Research Datalink between January 1, 1987 and February 28, 2016 (median age = 47 years, interquartile range [IQR] = 39-57, females = 7,308 [71.6%]). Patients were matched to 39,448 controls with no MS record by sex, year of birth, general practitioner, and year of registration (age = 47 years, IQR = 39-56, females = 28,248 [71.6%]). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using conditional logistic regression.
RESULTS: MS patients had significantly higher risk of presenting up to 10 years prior to index date with gastric, intestinal, urinary, and anorectal disturbances, anxiety, depression, insomnia, fatigue, headache, and various types of pain. MS risk progressively increased with each additional symptom presented (0-2 years: OR = 1.51, 95% CI = 1.47-1.55, p < 0.001; 2-5 years: OR = 1.29, 95% CI = 1.25-1.33, p < 0.001; 5-10 years: OR = 1.20, 95% CI = 1.15-1.26, p < 0.001). Sensitivity analyses in patients with age at index < 40 years and no neurological disturbances prior to symptoms of interest showed consistent results.
INTERPRETATION: Various clinical disturbances precede MS diagnosis by several years, supporting a prodromal phase to the disease and improving our clinical knowledge of early MS. Integrating these symptoms in the diagnostic procedure may help earlier disease identification. Ann Neurol 2018.
© 2018 American Neurological Association.

Entities:  

Mesh:

Year:  2018        PMID: 29740872     DOI: 10.1002/ana.25247

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  29 in total

Review 1.  Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications.

Authors:  Mario Habek
Journal:  Clin Auton Res       Date:  2019-04-08       Impact factor: 4.435

2.  Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.

Authors:  Raffaele Palladino; Ruth Ann Marrie; Azeem Majeed; Jeremy Chataway
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

3.  Autonomic nervous system: a key player in prodromal multiple sclerosis?

Authors:  Mario Habek; Magdalena Krbot Skorić
Journal:  Clin Auton Res       Date:  2020-03-11       Impact factor: 4.435

4.  Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.

Authors:  Kjetil Bjornevik; Kassandra L Munger; Marianna Cortese; Christian Barro; Brian C Healy; David W Niebuhr; Ann I Scher; Jens Kuhle; Alberto Ascherio
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

Review 5.  From the prodromal stage of multiple sclerosis to disease prevention.

Authors:  Ruth Ann Marrie; Mark Allegretta; Lisa F Barcellos; Bruce Bebo; Peter A Calabresi; Jorge Correale; Benjamin Davis; Philip L De Jager; Christiane Gasperi; Carla Greenbaum; Anne Helme; Bernhard Hemmer; Pamela Kanellis; Walter Kostich; Douglas Landsman; Christine Lebrun-Frenay; Naila Makhani; Kassandra L Munger; Darin T Okuda; Daniel Ontaneda; Ronald B Postuma; Jacqueline A Quandt; Sharon Roman; Shiv Saidha; Maria Pia Sormani; Jon Strum; Pamela Valentine; Clare Walton; Kathleen M Zackowski; Yinshan Zhao; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2022-07-15       Impact factor: 44.711

Review 6.  The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.

Authors:  Melanie Filser; Axel Buchner; Gereon Rudolf Fink; Stefan M Gold; Iris-Katharina Penner
Journal:  J Neurol       Date:  2022-09-21       Impact factor: 6.682

7.  Prefrontal-amygdala emotion regulation and depression in multiple sclerosis.

Authors:  Lil Meyer-Arndt; Joseph Kuchling; Jelena Brasanac; Andrea Hermann; Susanna Asseyer; Judith Bellmann-Strobl; Friedemann Paul; Stefan M Gold; Martin Weygandt
Journal:  Brain Commun       Date:  2022-06-13

Review 8.  Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.

Authors:  Giulia Menculini; Elena Chipi; Federico Paolini Paoletti; Lorenzo Gaetani; Pasquale Nigro; Simone Simoni; Andrea Mancini; Nicola Tambasco; Massimiliano Di Filippo; Alfonso Tortorella; Lucilla Parnetti
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 9.  The multiple sclerosis prodrome.

Authors:  Naila Makhani; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2021-06-21       Impact factor: 42.937

Review 10.  Fatigue as the Chief Complaint–Epidemiology, Causes, Diagnosis, and Treatment.

Authors:  Peter Maisel; Erika Baum; Norbert Donner-Banzhoff
Journal:  Dtsch Arztebl Int       Date:  2021-08-23       Impact factor: 8.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.